Myszkowski Kenneth Allen
Known title: Chief Financial OfficerCIK: 0001486672
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 8,000 | $158K | 1/7/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 10,000 | $197K | 1/7/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 17,765 | $350K | 1/6/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 9,402 | $189K | 1/6/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 100,000 | $0 | 1/4/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 40,000 | $1.4M | 3/6/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,400 | $48K | 1/5/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 5,800 | $203K | 1/5/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 8,904 | $317K | 1/5/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 75,000 | $0 | 1/4/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 15,000 | $543K | 6/27/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 60,000 | $0 | 1/4/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 30,625 | $1.2M | 12/29/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 16,528 | $1.0M | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,786 | $242K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,778 | $239K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 15,908 | $962K | 1/5/2022 | View on chart |
| ARWR | ▲ Buy | Grant | 60,000 | $0 | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.